In this role, Dr. Jenkins will be responsible for expanding Catalent's business growth in fast-dissolve technology across the world. He will be based in Swindon, UK.
Catalent's proprietary, market-leading Zydis fast-dissolve technology has been used in multiple therapeutic segments globally. Catalent also recently acquired the development rights to Lyopan® fast dissolve technology which offers the potential for improved taste-masking capabilities and may increase the range of drugs and consumer products that can be used in a fast dissolve dosage form. In addition, Catalent has broad controlled release drug delivery capabilities to help improve therapeutic profiles, patient adherence and bioavailability of treatments.
Prior to joining Catalent, Dr. Jenkins was the Chief Executive Officer of Adjuvantix, a UK-based biotechnology company, where he was responsible for all commercial activities and external funding. Prior to that, Dr. Jenkins was a Director of his own small privately-held healthcare consultancy called Ravenhill, where he advised clients on a broad range of strategic areas in the field of drug delivery, strategy formulation, business development and M&A. Earlier on in his career, he worked in increasingly senior business development roles with Phoqus Pharmaceuticals and West Pharmaceutical Services, managing sales and marketing teams across the globe.
Dr. Jenkins has a first-class honors degree in Biology and a Ph.D. in Immunology from the University of Plymouth and an Executive MBA from the London Business School.
“As Catalent continues its investment into drug delivery technology talent, capabilities and capacity, I am excited to have Paul join the Catalent team to help us grow our fast-dissolve technology platform. He brings a wealth of drug delivery and commercial experience to Catalent,” said Will Downie, Senior Vice President of Global Sales and Marketing for Catalent.
Catalent's proprietary, market-leading Zydis fast-dissolve technology has been used in multiple therapeutic segments globally. Catalent also recently acquired the development rights to Lyopan® fast dissolve technology which offers the potential for improved taste-masking capabilities and may increase the range of drugs and consumer products that can be used in a fast dissolve dosage form. In addition, Catalent has broad controlled release drug delivery capabilities to help improve therapeutic profiles, patient adherence and bioavailability of treatments.
Prior to joining Catalent, Dr. Jenkins was the Chief Executive Officer of Adjuvantix, a UK-based biotechnology company, where he was responsible for all commercial activities and external funding. Prior to that, Dr. Jenkins was a Director of his own small privately-held healthcare consultancy called Ravenhill, where he advised clients on a broad range of strategic areas in the field of drug delivery, strategy formulation, business development and M&A. Earlier on in his career, he worked in increasingly senior business development roles with Phoqus Pharmaceuticals and West Pharmaceutical Services, managing sales and marketing teams across the globe.
Dr. Jenkins has a first-class honors degree in Biology and a Ph.D. in Immunology from the University of Plymouth and an Executive MBA from the London Business School.
“As Catalent continues its investment into drug delivery technology talent, capabilities and capacity, I am excited to have Paul join the Catalent team to help us grow our fast-dissolve technology platform. He brings a wealth of drug delivery and commercial experience to Catalent,” said Will Downie, Senior Vice President of Global Sales and Marketing for Catalent.
Companies in this article
